<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121497</url>
  </required_header>
  <id_info>
    <org_study_id>5759</org_study_id>
    <nct_id>NCT01121497</nct_id>
  </id_info>
  <brief_title>The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of physostigmine in&#xD;
      combination with sedation for colonoscopy can minimize the cognitive decline at the time of&#xD;
      hospital discharge&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Physostigmine, a tertiary cholinesterase inhibitor, which prevents the breakdown of ACh by&#xD;
      inhibiting the enzyme acetylcholinesterase (AChE), crosses the blood-brain barrier (BBB), and&#xD;
      elevates brain ACh levels. Physostigmine has been shown to improve attention, and performance&#xD;
      in working memory. It has also been shown to produce analgesia following systemic or central&#xD;
      administration.&#xD;
&#xD;
      Patients undergoing colonoscopy under sedation of propofol and fentanyl show cognitive&#xD;
      decline in the immediate period following the procedure. In this study, half the patients&#xD;
      will receive physostigmine in combination with the sedation, and their cognitive functioning&#xD;
      at the time of hospital discharge will be assessed by standard neuropsychological tests, and&#xD;
      compared to that of patients without physostigmine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive functioning assessed by standard neuropsychological tests</measure>
    <time_frame>At time of hospital discharge following colonoscopy procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Physostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonoscopy sedation with or without physostigmine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physostigmine</intervention_name>
    <description>Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure</description>
    <arm_group_label>Physostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over18 years old&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Fluency in Hebrew, Russian, or Arabic&#xD;
&#xD;
          -  Absence of serious hearing or vision impairment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head trauma, neurological diseases, alcoholism, drug abuse, consumption of&#xD;
             psychotropic drugs or antidepressants&#xD;
&#xD;
          -  Heart failure (NYHA &gt; 3)&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Respiratory problems (asthma, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bezion Beilin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasharon Hospital, Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benzion Beilin, MD</last_name>
    <phone>972-3-937-2469</phone>
    <email>beilinb@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hasharon Hospital, Rabin Medical Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49372</zip>
        <country>Israel</country>
      </address>
    </facility>
    <investigator>
      <last_name>Benzion Beilin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>May 9, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>May 11, 2010</last_update_submitted>
  <last_update_submitted_qc>May 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Benzion Beilin</name_title>
    <organization>Hasharon Hospital, Rabin Medical Center</organization>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Cognitive decline</keyword>
  <keyword>Physostigmine</keyword>
  <keyword>Colonoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Physostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

